PSIL AdvisorShares Psychedelics ETF

ETF on NYSE (US) · Actively managed · Listing

Daily holdings file Nov 17, 2026 Published at advisorshares.com
Book $38.1M 29 positions
Line items 29
In top 10 70%
Largest holding: Definium Therapeutics, Inc. ($4.50M) 11.8%
Portfolio date Nov 17, 2026

Changes appear once four weeks of holdings are on file.

Largest holding: Definium Therapeutics, Inc., 153,124 shares ($4.50M).

Definium Therapeutics, Inc.: 11.8% COMPASS Pathways Plc: 10.4% Helus Pharma Inc.: 7.4% Eli Lilly and Company: 6.9% Neurocrine Biosciences, Inc.: 6.5% AbbVie Inc.: 6.2% Indivior Pharmaceuticals, Inc.: 5.4% Relmada Therapeutics, Inc.: 5.2% Seaport Therapeutics, Inc.: 5.2% Johnson & Johnson: 5.0% The other 19 positions: 29.9% $38.1M Holdings value
Current positions Top 10 % of book
Definium Therapeutics, Inc. DFTX $4.50M 11.8%
COMPASS Pathways Plc CMPS $3.95M 10.4%
Helus Pharma Inc. HELP $2.82M 7.4%
Eli Lilly and Company LLY $2.63M 6.9%
Neurocrine Biosciences, Inc. NBIX $2.48M 6.5%
AbbVie Inc. ABBV $2.36M 6.2%
Indivior Pharmaceuticals, Inc. INDV $2.07M 5.4%
Relmada Therapeutics, Inc. RLMD $2.00M 5.2%
Seaport Therapeutics, Inc. SPTX $1.99M 5.2%
Johnson & Johnson JNJ $1.91M 5.0%

Slices are % of holdings value.

Healthcare: 98.7% Unclassified: 1.3% 1 sectors
Sectors % of long value
Healthcare 98.7%
Unclassified 1.3%
Biotechnology: 70.0% Drug Manufacturers - General: 18.1% Drug Manufacturers - Specialty & Generic: 6.9% Medical Devices: 3.7% Unclassified: 1.3% 4 industries
Industries % of long value
Biotechnology 70.0%
Drug Manufacturers - General 18.1%
Drug Manufacturers - Specialty & Generic 6.9%
Medical Devices 3.7%
Unclassified 1.3%

Source: the fund's own published holdings, the portfolio of Nov 17, 2026 (advisorshares.com). Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.

Objective

The AdvisorShares Psychedelics ETF (the "Fund") seeks long-term capital appreciation.

Principal investment strategies

The Fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by primarily investing in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The Fund invests in exchange-listed equity securities, including common and preferred stock of U.S. and foreign mid-, small- and micro-capitalization companies. The Fund also may invest in total return swaps intended to provide exposure to such companies. Under normal circumstances, Fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in (i) securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and (ii) derivatives that have economic characteristics similar to such securities. Psychedelic drugs, also known as hallucinogens, are a group of substances, including psilocybin, that are used to change and enhance sensory perceptions, thought processes, and energy levels. Psychedelic medicines, therapeutics, and healthcare treatments may be used in the treatment of illnesses such as depression, addiction, anxiety and post-traumatic stress disorder. Psychedelic medicine companies include life sciences companies having significant business activities in, or significant exposure to, the psychedelics industry, including producers or distributors of psychedelic medicines, biotechnology companies engaged in research and development of psychedelic medicines, and companies that provide psychotherapy treatments and mental health services using psychedelics. The Fund does not consider cannabis to be a psychedelic drug. The Fund will not invest directly in or hold ownership in any companies that engage in psychedelics-related business unless permitted by national and local laws of the relevant jurisdiction including, but not limited to, U.S. federal and state laws. The Fund concentrates (i.e., invests more than 25% of its total assets) in the pharmaceuticals, biotechnology & life sciences industry group within the health care sector. The Fund is non-diversified and may invest a greater percentage of its assets in a particular issuer than a diversified fund. 2 The Advisor may use a variety of methods for security selection. As the Fund primarily focuses on certain industries, the Advisor intends to select companies with dominant positions in their respective markets, or those in unique positions for growth and expansion. The Advisor will utilize numerous outside analyst ratings and stock selection rating tools. In addition, the Advisor may invest the Fund's assets in lesser-known companies that the Advisor believes have a unique opportunity for growth. At times, the Advisor may aim to buy certain out-of-favor stocks believed to be at prices below their future potential value, as measured by the Advisor or outside analysts. The Fund may sell a security when the Advisor believes that the security is overvalued or better investment opportunities are available, or to limit position size within the Fund's portfolio.

Management and Contact

Adviser
AdvisorShares Investments, LLC
Phone
877.843.3831

Holdings as of Nov 17, 2026

29 lines, 22 linked, weights sum to 99.98% · Actively managed (N-CEN)

Holding Ticker / identifier Type Shares Change Weight Market value
DEFINIUM THERAPEUTICS INC DFTX 24477V105 Equity 153,124 0 11.81% $ 4.499M
COMPASS PATHWAYS PLC CMPS 20451W101 Equity 494,395 0 10.35% $ 3.945M
HELUS PHARMA INC HELP 423492107 Equity 392,147 0 7.41% $ 2.823M
ELI LILLY & CO LLY 532457108 Equity 1,860 0 6.91% $ 2.633M
NEUROCRINE BIOSCIENCES INC NBIX 64125C109 Equity 14,954 0 6.51% $ 2.481M
ABBVIE INC ABBV 00287Y109 Equity 8,071 0 6.20% $ 2.363M
SUPERNUS INC SUPN 45579U109 Equity 71,341 0 5.44% $ 2.072M
RELMADA THERAPEUTICS INC RLMD 75955J402 Equity 663,176 0 5.24% $ 1.996M
SEAPORT THERAPEUTICS INC SPTX 81221K108 Equity 109,334 0 5.21% $ 1.987M
JOHNSON & JOHNSON JNJ 478160104 Equity 6,842 0 5.00% $ 1.907M
GH RESEARCH PLC GHRS G3855L106 Equity 102,038 0 4.89% $ 1.864M
NRX PHARMACEUTICALS INC NRXP 629444209 Equity 740,811 0 4.76% $ 1.815M
ALTO NEUROSCIENCE INC ANRO 02157Q109 Equity 71,847 0 4.70% $ 1.79M
NEURONETICS INC STIM 64131A105 Equity 1,098,644 0 3.69% $ 1.406M
BRIGHT MINDS BIOSCIENCES INC DRUG 10919W405 Equity 48,217 0 2.60% $ 988.931K
NEUPHORIA THERAPEUTICS INC NEUP 64136E102 Equity 290,653 0 1.73% $ 659.782K
PSYENCE BIOMEDICAL LTD PBM 74449F407 Equity 258,157 0 1.70% $ 647.974K
QUANTUM BIOPHARMA-B SUB VOT QNTM 74764Y205 Equity 391,932 0 1.64% $ 623.172K
OPTIMI HEALTH CORP OPTH 68405H308 Equity 266,914 0 1.47% $ 560.519K
BLACKROCK TREASURY TRUST INSTL 62
X9USDBLYT Money market 344,797.13 +216,150.39 0.90% $ 344.797K
INCANNEX HEALTHCARE INC IXHL 45333F208 Equity 156,359 0 0.71% $ 272.065K
NUMINUS WELLNESS INC
NUMIF 67054W103 Equity 9,748,746 0 0.44% $ 166.704K
IGC PHARMA INC IGC 45408X308 Equity 872,689 0 0.43% $ 163.978K
SILO PHARMA INC SILO 82711P300 Equity 96,113 0 0.42% $ 161.47K
CASH
Cash short -66,929.47 −217,026.61 -0.18% $ -66.929K
CONTRA ATAIBECKLEY INC
046CVR015 Equity 606,427 0 — —
QUANTUM BIOPHARMA LTD
747CNT053 Equity 46,617 0 — —
SAGE THERAPEUTICS CVR
786CVR019 Equity 89,780 0 — —
UNBUZZD WELLNESS INC
BMY9R83 Equity 10,967 0 — —

Trades Nov 16, 2026 to Nov 17, 2026

Holding Ticker Action Before After Change Value

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up